179 related articles for article (PubMed ID: 36399351)
1. Reforming Reimbursement for the US Food and Drug Administration's Accelerated Approval Program to Support State Medicaid Programs.
Sachs RE; Donohue JM; Dusetzina SB
JAMA Health Forum; 2022 Nov; 3(11):e224115. PubMed ID: 36399351
[TBL] [Abstract][Full Text] [Related]
2. Medicaid and Accelerated Approval: Spending on Drugs with and without Proven Clinical Benefits.
Sachs RE; Jazowski SA; Gavulic KA; Donohue JM; Dusetzina SB
J Health Polit Policy Law; 2022 Dec; 47(6):673-690. PubMed ID: 35867545
[TBL] [Abstract][Full Text] [Related]
3. Improving Food and Drug Administration-Centers for Medicare and Medicaid Services Coordination for Drugs Granted Accelerated Approval.
Neumann PJ; Crummer E; Chambers JD; Tunis SR
Milbank Q; 2023 Dec; 101(4):1047-1075. PubMed ID: 37644739
[TBL] [Abstract][Full Text] [Related]
4. Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval.
Sachs RE; Gavulic KA; Donohue JM; Dusetzina SB
JAMA Health Forum; 2021 Oct; 2(10):e213177. PubMed ID: 35977163
[TBL] [Abstract][Full Text] [Related]
5. Extending the US Food and Drug Administration's Postmarket Authorities.
Fernandez Lynch H; Sachs RE; Lee S; Herder M; Ross JS; Ramachandran R
JAMA Health Forum; 2023 Jun; 4(6):e231313. PubMed ID: 37294583
[TBL] [Abstract][Full Text] [Related]
6. Potential policy reforms to strengthen the accelerated approval pathway.
Kaltenboeck A; Mehlman A; Pearson SD
J Comp Eff Res; 2021 Nov; 10(16):1177-1186. PubMed ID: 34427103
[TBL] [Abstract][Full Text] [Related]
7. Analysis of FDA's Accelerated Approval Program Performance December 1992-December 2021.
Beakes-Read G; Neisser M; Frey P; Guarducci M
Ther Innov Regul Sci; 2022 Sep; 56(5):698-703. PubMed ID: 35900722
[TBL] [Abstract][Full Text] [Related]
8. Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017.
Skydel JJ; Egilman AC; Wallach JD; Ramachandran R; Gupta R; Ross JS
JAMA Health Forum; 2022 May; 3(5):e221158. PubMed ID: 35977252
[TBL] [Abstract][Full Text] [Related]
9. Aducanumab, Accelerated Approvals & the Agency: Why the FDA Needs Structural Reform.
Herder M
J Law Med Ethics; 2023; 51(4):900-919. PubMed ID: 38477277
[TBL] [Abstract][Full Text] [Related]
10. Physician Perspectives on the Food and Drug Administration's Decision to Grant Accelerated Approval to Aducanumab for Alzheimer's Disease.
Dhruva SS; Kesselheim AS; Woloshin S; Ji RZ; Lu Z; Darrow JJ; Redberg RF
Clin Pharmacol Ther; 2023 Sep; 114(3):614-617. PubMed ID: 37218658
[TBL] [Abstract][Full Text] [Related]
11. Raising Medicaid Rebates For Drugs With Accelerated Approval.
Rome BN; Kesselheim AS
Health Aff (Millwood); 2021 Dec; 40(12):1935-1942. PubMed ID: 34871070
[TBL] [Abstract][Full Text] [Related]
12. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
Puthumana J; Miller JE; Kim J; Ross JS
JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
[TBL] [Abstract][Full Text] [Related]
13. Great Trees Require Strong Roots: Evaluating Data and Delegation Doctrine Underlying Proposed Reforms to FDA's Accelerated Approval Program.
Deshmukh AD
J Law Med Ethics; 2023; 51(4):920-925. PubMed ID: 38477271
[TBL] [Abstract][Full Text] [Related]
14. Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006-2021: a cross-sectional study.
Xie J; Li J; Liu Y; Wang H; Wang Y; Yang Y; Chen Y; Jiang R; Shao R
BMJ Open; 2023 Jun; 13(6):e069132. PubMed ID: 37286329
[TBL] [Abstract][Full Text] [Related]
15. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval.
Gyawali B; Hey SP; Kesselheim AS
JAMA Intern Med; 2019 Jul; 179(7):906-913. PubMed ID: 31135808
[TBL] [Abstract][Full Text] [Related]
17. Comparing patient access to pharmaceuticals in the UK and US.
Cohen J; Cairns C; Paquette C; Faden L
Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
[TBL] [Abstract][Full Text] [Related]
18. The FDA Oncology Center of Excellence and precision medicine.
Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
[TBL] [Abstract][Full Text] [Related]
19. Pharmaceutical Drugs of Uncertain Value, Lifecycle Regulation at the US Food and Drug Administration, and Institutional Incumbency.
Herder M
Milbank Q; 2019 Sep; 97(3):820-857. PubMed ID: 31407412
[TBL] [Abstract][Full Text] [Related]
20. The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.
Wallach JD; Ross JS; Naci H
Clin Trials; 2018 Jun; 15(3):219-229. PubMed ID: 29871509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]